JP2024533482A - Ｓｓｔｒ４アゴニスト塩 - Google Patents

Ｓｓｔｒ４アゴニスト塩 Download PDF

Info

Publication number
JP2024533482A
JP2024533482A JP2024516362A JP2024516362A JP2024533482A JP 2024533482 A JP2024533482 A JP 2024533482A JP 2024516362 A JP2024516362 A JP 2024516362A JP 2024516362 A JP2024516362 A JP 2024516362A JP 2024533482 A JP2024533482 A JP 2024533482A
Authority
JP
Japan
Prior art keywords
compound
formula
compound according
patient
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2024516362A
Other languages
English (en)
Japanese (ja)
Inventor
アンドリュー コーツ，デイビッド
マイケル レミック，デイビッド
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2024533482A publication Critical patent/JP2024533482A/ja
Priority to JP2025071176A priority Critical patent/JP2025111617A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024516362A 2021-09-14 2022-09-14 Ｓｓｔｒ４アゴニスト塩 Withdrawn JP2024533482A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025071176A JP2025111617A (ja) 2021-09-14 2025-04-23 Ｓｓｔｒ４アゴニスト塩

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163243785P 2021-09-14 2021-09-14
US63/243,785 2021-09-14
PCT/US2022/076401 WO2023044326A1 (en) 2021-09-14 2022-09-14 Sstr4 agonist salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025071176A Division JP2025111617A (ja) 2021-09-14 2025-04-23 Ｓｓｔｒ４アゴニスト塩

Publications (1)

Publication Number Publication Date
JP2024533482A true JP2024533482A (ja) 2024-09-12

Family

ID=83508479

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024516362A Withdrawn JP2024533482A (ja) 2021-09-14 2022-09-14 Ｓｓｔｒ４アゴニスト塩
JP2025071176A Pending JP2025111617A (ja) 2021-09-14 2025-04-23 Ｓｓｔｒ４アゴニスト塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025071176A Pending JP2025111617A (ja) 2021-09-14 2025-04-23 Ｓｓｔｒ４アゴニスト塩

Country Status (19)

Country Link
US (2) US11834435B2 (https=)
EP (1) EP4402136A1 (https=)
JP (2) JP2024533482A (https=)
KR (1) KR20240056751A (https=)
CN (1) CN117940413A (https=)
AR (1) AR127055A1 (https=)
AU (1) AU2022348561B2 (https=)
CA (1) CA3231451A1 (https=)
CL (2) CL2024000683A1 (https=)
CO (1) CO2024003038A2 (https=)
CR (1) CR20240118A (https=)
DO (1) DOP2024000050A (https=)
EC (1) ECSP24020256A (https=)
IL (1) IL311251A (https=)
JO (1) JOP20240053A1 (https=)
MX (1) MX2024003119A (https=)
PE (1) PE20240885A1 (https=)
TW (3) TWI860849B (https=)
WO (1) WO2023044326A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860849B (zh) * 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
AU2024236692A1 (en) * 2023-03-10 2025-10-16 Eli Lilly And Company Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
WO2025096300A1 (en) * 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
TW202600537A (zh) 2024-03-11 2026-01-01 美商美國禮來大藥廠 Ｓｓｔｒ４促效劑化合物及其組合物
GB202408483D0 (en) 2024-06-13 2024-07-31 Maxion Therapeutics Ltd Receptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518430A (ja) * 2013-05-17 2016-06-23 セントレクシオン セラピューティクス コーポレイション 新規ソマトスタチン受容体亜型４（ｓｓｔｒ４）作動薬

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159941A (en) 1996-05-14 2000-12-12 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US6063796A (en) 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
EP1565436B1 (en) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
FI20031454A0 (fi) 2003-10-06 2003-10-06 Juvantia Pharma Ltd Oy Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja
US20100004339A1 (en) 2003-10-06 2010-01-07 Oy Juvantia Pharma Ltd. Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists
RS20060190A (sr) 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
WO2007029086A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
GB0616574D0 (en) 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CA2729767A1 (en) 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
WO2010059922A1 (en) 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
EP2685828A4 (en) 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
CN102675290B (zh) 2011-03-18 2014-11-12 山东亨利医药科技有限责任公司 含有并环的二氢吡唑类化合物
KR101556318B1 (ko) 2013-05-15 2015-10-01 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
WO2016075239A1 (en) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists
BR112017009595A2 (pt) 2014-11-14 2017-12-19 Boehringer Ingelheim Int morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
JP7774312B2 (ja) 2020-05-21 2025-11-21 クワンチョウ フェルミオン テクノロジー カンパニー リミテッド 縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用
WO2021233428A1 (zh) 2020-05-21 2021-11-25 广州费米子科技有限责任公司 含氮饱和杂环化合物及其制备方法、药物组合物和应用
WO2022012534A1 (zh) 2020-07-13 2022-01-20 广州费米子科技有限责任公司 含氮杂环化合物、药物组合物和应用
TWI860849B (zh) * 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518430A (ja) * 2013-05-17 2016-06-23 セントレクシオン セラピューティクス コーポレイション 新規ソマトスタチン受容体亜型４（ｓｓｔｒ４）作動薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6019015773, 2002, pages 305 - 311, ISSN: 0005640486 *

Also Published As

Publication number Publication date
CN117940413A (zh) 2024-04-26
MX2024003119A (es) 2024-04-09
ECSP24020256A (es) 2024-04-30
TWI860849B (zh) 2024-11-01
TWI822326B (zh) 2023-11-11
TW202400577A (zh) 2024-01-01
AU2022348561B2 (en) 2025-05-22
IL311251A (en) 2024-05-01
US12486249B2 (en) 2025-12-02
AR127055A1 (es) 2023-12-13
EP4402136A1 (en) 2024-07-24
JP2025111617A (ja) 2025-07-30
CA3231451A1 (en) 2023-03-23
TW202444703A (zh) 2024-11-16
CR20240118A (es) 2024-04-25
CO2024003038A2 (es) 2024-04-18
TW202330492A (zh) 2023-08-01
CL2025002158A1 (es) 2025-11-07
WO2023044326A1 (en) 2023-03-23
PE20240885A1 (es) 2024-04-24
US11834435B2 (en) 2023-12-05
JOP20240053A1 (ar) 2024-03-12
CL2024000683A1 (es) 2024-08-23
KR20240056751A (ko) 2024-04-30
DOP2024000050A (es) 2024-04-30
AU2022348561A1 (en) 2024-03-14
US20230099116A1 (en) 2023-03-30
US20240067628A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
TWI860849B (zh) Sstr4促效劑鹽
EP0984779A1 (en) Somatostatin agonists
CN111433196B (zh) 缓激肽b2受体拮抗剂及其用途
EP0977751A1 (en) Somatostatin agonists
EP1023061A1 (en) Somatostatin agonists
WO2023124824A1 (zh) 一种glp-1激动剂的盐及其晶型和在医药上的应用
CN113906020B (zh) 环状缓激肽b2受体拮抗剂
CN111132984A (zh) 凋亡信号调节激酶1抑制剂的盐及其晶型
WO2024125446A9 (zh) 盐型的glp-1受体激动剂、其晶型和制备方法及其药物组合物和用途
WO2023130878A1 (zh) 一种glp-1激动剂盐及其晶型及在医药上的应用
TW202444710A (zh) 一種脂蛋白化合物晶型及其製備方法
WO2021100019A1 (en) Prodrugs of abiraterone
CN110872277A (zh) N-取代芳环-2-氨基嘧啶类化合物及用途
WO2019096112A1 (zh) 一种取代的苯并咪唑化合物及包含该化合物的组合物
CN114072406A (zh) Flna-结合化合物及其盐酸盐的固体多晶型物
JP7707406B2 (ja) Ｍｏｒ受容体アゴニストの薬学的に許容できる塩、その多形体及びその使用
EA050624B1 (ru) Соли агониста sstr4
WO2023061372A1 (zh) 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
JP2023543080A (ja) ピロロ複素環系誘導体の結晶及びその製造方法
CN111499627A (zh) 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型
EP4562008A1 (en) Substituted pyrazolyl-pyridinyl compounds as ligand directed degraders of irak3
WO2024213088A1 (zh) 嘧啶三并环衍生物的结晶及用途
EP4703363A1 (en) Salt form and crystal form of thienopyrimidine compound, and preparation method therefor and use thereof
TW202110429A (zh) 環狀緩激肽b2受體拮抗劑
CN117343073A (zh) 含噻吩并环类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240313

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251020

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260305